LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Levofloxacin In Dextrose 5% In Plastic Container, and when can generic versions of Levofloxacin In Dextrose 5% In Plastic Container launch?
Levofloxacin In Dextrose 5% In Plastic Container is a drug marketed by Baxter Hlthcare Corp, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma Farmaceutica, Hospira, Inforlife, and Knack. and is included in eight NDAs.
The generic ingredient in LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER is levofloxacin. There are thirty-one drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the levofloxacin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Levofloxacin In Dextrose 5% In Plastic Container
A generic version of LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER was approved as levofloxacin by RISING on December 20th, 2010.
Summary for LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER
| US Patents: | 0 |
| Applicants: | 8 |
| NDAs: | 8 |
| Finished Product Suppliers / Packagers: | 8 |
| Clinical Trials: | 275 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER at DailyMed |
Recent Clinical Trials for LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Yi Yang | N/A |
| Melva Louisa | Phase 1 |
| Tanta University | N/A |
See all LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER clinical trials
Anatomical Therapeutic Chemical (ATC) Classes for LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER
US Patents and Regulatory Information for LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER
EU/EMA Drug Approvals for LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Chiesi Farmaceutici S.p.A | Quinsair | levofloxacin | EMEA/H/C/002789 Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.Consideration should be given to official guidance on the appropriate use of antibacterial agents. |
Authorised | no | no | no | 2015-03-25 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
